ONE-YEAR RESULTS OF HALF- VERSUS STANDARD-DOSE PHOTODYNAMIC THERAPY COMBINED WITH RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
OBJECTIVE
To explore the efficacy of half-dose verteporfin photodynamic therapy (hd-PDT) and standard-dose photodynamic therapy (sd-PDT), when combined with ranibizumab in the treatment of polypoidal choroidal vasculopathy.


METHODS
Subjects were allocated to either the hd-PDT arm or the sd-PDT arm. All subjects received an injection of ranibizumab and PDT treatment (dosage according to allocation) at baseline. Subjects were followed up monthly for 12 months, and re-treatment were given at each visit if criteria were met.


RESULTS
There were 26 subjects in the hd-PDT arm and 32 in the sd-PDT arm. Overall mean age was 69.3 ± 9.4 years. Baseline demographics and ocular features did not differ significantly between the two arms. Improvement in vision and reduction in central retinal thickness were similar between the two arms. When presenting, visual acuity was better than 20/50 (logarithm of the minimum angle of resolution 0.4), or when there were three or less polyps angiogram, those treated with hd-PDT tended to perform better than those treated with sd-PDT.


CONCLUSIONS
In general, hd-PDT was able to produce similar results as sd-PDT. Subgroup analysis revealed superior results with hd-PDT when baseline vision was 20/50 or better, or when there were three or less polyps on indocyanine green angiography.
Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Ian Y
IY
Wong
Department of Ophthalmology, Peking University People's Hospital, Beijing, China.
Xuan
X
Shi
Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Rita
R
Gangwani
Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Lawrence P
LP
Iu
Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Nicholas
N
Fung
Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Qing
Q
Li
Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Alex L K
ALK
Ng
Department of Ophthalmology, Peking University People's Hospital, Beijing, China.
Xiaoxin
X
Li
D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D015862:Choroid Diseases / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011446:Prospective Studies; D000069579:Ranibizumab / Q000627:therapeutic use*; D012160:Retina / Q000473:pathology; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D017319:Photosensitizing Agents; D000069579:Ranibizumab